Cargando…
Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats
BACKGROUND: Nanosilver is used in a variety of medical and consumer products because of its antibacterial activity. This wide application results in an increased human exposure. Knowledge on the systemic toxicity of nanosilver is, however, relatively scarce. In a previous study, the systemic toxicit...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052812/ https://www.ncbi.nlm.nih.gov/pubmed/24885556 http://dx.doi.org/10.1186/1743-8977-11-21 |
_version_ | 1782320294674825216 |
---|---|
author | Vandebriel, Rob J Tonk, Elisa CM de la Fonteyne-Blankestijn, Liset J Gremmer, Eric R Verharen, Henny W van der Ven, Leo T van Loveren, Henk de Jong, Wim H |
author_facet | Vandebriel, Rob J Tonk, Elisa CM de la Fonteyne-Blankestijn, Liset J Gremmer, Eric R Verharen, Henny W van der Ven, Leo T van Loveren, Henk de Jong, Wim H |
author_sort | Vandebriel, Rob J |
collection | PubMed |
description | BACKGROUND: Nanosilver is used in a variety of medical and consumer products because of its antibacterial activity. This wide application results in an increased human exposure. Knowledge on the systemic toxicity of nanosilver is, however, relatively scarce. In a previous study, the systemic toxicity of 20 nm silver nanoparticles (Ag-NP) was studied in a 28-day repeated-dose toxicity study in rats. Ag-NP were intravenously administered with a maximum dose of 6 mg/kg body weight (bw)/day. Several immune parameters were affected: reduced thymus weight, increased spleen weight and spleen cell number, a strongly reduced NK cell activity, and reduced IFN-γ production were observed. METHODS: Prompted by these affected immune parameters, we wished to assess exposure effects on the functional immune system. Therefore, in the present study the T-cell dependent antibody response (TDAR) to keyhole limpet hemocyanin (KLH) was measured in a similar 28-day intravenous repeated-dose toxicity study. In addition, a range of immunological parameters was measured. Data obtained using the benchmark dose (BMD) approach were analyzed by fitting dose-response models to the parameters measured. RESULTS: A reduction in KLH-specific IgG was seen, with a lowest 5% lower confidence bound of the BMD (BMDL) of 0.40 mg/kg bw/day. This suggests that Ag-NP induce suppression of the functional immune system. Other parameters sensitive to Ag-NP exposure were in line with our previous study: a reduced thymus weight with a BMDL of 0.76 mg/kg bw/day, and an increased spleen weight, spleen cell number, and spleen cell subsets, with BMDLs between 0.36 and 1.11 mg/kg bw/day. Because the effects on the spleen are not reflected by increased KLH-specific IgG, they, however, do not suggest immune stimulation. CONCLUSIONS: Intravenous Ag-NP administration in a 28-day repeated-dose toxicity study induces suppression of the functional immune system. This finding underscores the importance to study the TDAR to evaluate immunotoxicity and not to rely solely on measuring immune cell subsets. |
format | Online Article Text |
id | pubmed-4052812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40528122014-06-12 Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats Vandebriel, Rob J Tonk, Elisa CM de la Fonteyne-Blankestijn, Liset J Gremmer, Eric R Verharen, Henny W van der Ven, Leo T van Loveren, Henk de Jong, Wim H Part Fibre Toxicol Research BACKGROUND: Nanosilver is used in a variety of medical and consumer products because of its antibacterial activity. This wide application results in an increased human exposure. Knowledge on the systemic toxicity of nanosilver is, however, relatively scarce. In a previous study, the systemic toxicity of 20 nm silver nanoparticles (Ag-NP) was studied in a 28-day repeated-dose toxicity study in rats. Ag-NP were intravenously administered with a maximum dose of 6 mg/kg body weight (bw)/day. Several immune parameters were affected: reduced thymus weight, increased spleen weight and spleen cell number, a strongly reduced NK cell activity, and reduced IFN-γ production were observed. METHODS: Prompted by these affected immune parameters, we wished to assess exposure effects on the functional immune system. Therefore, in the present study the T-cell dependent antibody response (TDAR) to keyhole limpet hemocyanin (KLH) was measured in a similar 28-day intravenous repeated-dose toxicity study. In addition, a range of immunological parameters was measured. Data obtained using the benchmark dose (BMD) approach were analyzed by fitting dose-response models to the parameters measured. RESULTS: A reduction in KLH-specific IgG was seen, with a lowest 5% lower confidence bound of the BMD (BMDL) of 0.40 mg/kg bw/day. This suggests that Ag-NP induce suppression of the functional immune system. Other parameters sensitive to Ag-NP exposure were in line with our previous study: a reduced thymus weight with a BMDL of 0.76 mg/kg bw/day, and an increased spleen weight, spleen cell number, and spleen cell subsets, with BMDLs between 0.36 and 1.11 mg/kg bw/day. Because the effects on the spleen are not reflected by increased KLH-specific IgG, they, however, do not suggest immune stimulation. CONCLUSIONS: Intravenous Ag-NP administration in a 28-day repeated-dose toxicity study induces suppression of the functional immune system. This finding underscores the importance to study the TDAR to evaluate immunotoxicity and not to rely solely on measuring immune cell subsets. BioMed Central 2014-05-07 /pmc/articles/PMC4052812/ /pubmed/24885556 http://dx.doi.org/10.1186/1743-8977-11-21 Text en Copyright © 2014 Vandebriel et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Vandebriel, Rob J Tonk, Elisa CM de la Fonteyne-Blankestijn, Liset J Gremmer, Eric R Verharen, Henny W van der Ven, Leo T van Loveren, Henk de Jong, Wim H Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats |
title | Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats |
title_full | Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats |
title_fullStr | Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats |
title_full_unstemmed | Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats |
title_short | Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats |
title_sort | immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052812/ https://www.ncbi.nlm.nih.gov/pubmed/24885556 http://dx.doi.org/10.1186/1743-8977-11-21 |
work_keys_str_mv | AT vandebrielrobj immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats AT tonkelisacm immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats AT delafonteyneblankestijnlisetj immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats AT gremmerericr immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats AT verharenhennyw immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats AT vandervenleot immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats AT vanloverenhenk immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats AT dejongwimh immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats |